Health Canada authorizes long-awaited drug to slow early-stage Alzheimer’s disease
October 28, 2025
October 28, 2025
TORONTO — Health Canada has authorized a drug shown to slow the progression of Alzheimer’s disease.
Lecanemab is the first medication approved in Canada that targets the buildup of amyloid plaque in the brain, which is believed to be an underlying cause of Alzheimer’s disease.
The drug is a lab-made antibody that binds to the amyloid proteins and helps neutralize and clear them from the brain.
Lecanemab must be administered in the early stages of dementia when there is mild cognitive impairment.
Adam Morrison, a spokesperson for the Alzheimer Society of Ontario, says patients and their families have been anxiously awaiting the approval of lecanemab — also known by its brand name Leqembi — in Canada.
Morrison said Alzheimer societies are urging Canada’s Drug Agency and provincial governments to quickly bring the drug to market and publicly fund it so all eligible patients can afford to take it, noting it costs about US$26,000 a year in other countries.
Mainstream NewsBed Bug Infestation Forces Closure of Fort Simpson Schools
Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.
Mainstream NewsThe Complex History of Bible Translations in Greenland and Labrador
Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.
Mainstream NewsInuit-Led Pirutsiagutiit Program Replaces Child First Initiative
Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.
Mainstream NewsWhitehorse Students Engage With Canadian Astronauts Aboard the ISS
Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.